Fuchs, Michael

Publishing since 1972 (Dinosaur)

Has published 172 publications in 38 years

Number of publications published per year by Fuchs, Michael. (Source : PubMed)

Distribution of publications types for Fuchs, Michael. (Source : PubMed)
(a publication can be of different types, so total may exceed publications count)

Recent publications

•  Eichenauer DA, Bredenfeld H, Haverkamp H, Müller H, Franklin J, Fuchs M, Borchmann P, Müller-Hermelink HK, Eich HT, Müller RP, Diehl V, Engert A. Hodgkin's lymphoma in adolescents treated with adult protocols: a report from the German Hodgkin study group.  J. Clin. Oncol.  2009;27;36  
•  Goebel JW, Pickardt T, Bedau M, Fuchs M, Lenk C, Paster I, Spranger TM, Stockter U, Bauer U, Cooper DN, Krawczak M. Legal and ethical consequences of international biobanking from a national perspective: the German BMB-EUCoop project.  Eur. J. Hum. Genet.  2009  
•  Puri P, Wiest MM, Cheung O, Mirshahi F, Sargeant C, Min HK, Contos MJ, Sterling RK, Fuchs M, Zhou H, Watkins SM, Sanyal AJ. The plasma lipidomic signature of nonalcoholic steatohepatitis.  Hepatology  2009;50;6  
•  Brader JM, Voigtmann T, Fuchs M, Larson RG, Cates ME. Glass rheology: From mode-coupling theory to a dynamical yield criterion.  Proc. Natl. Acad. Sci. U.S.A.  2009;106;36  
•  Vigne E, Marmonier A, Komar V, Lemaire O, Fuchs M. Genetic structure and variability of virus populations in cross-protected grapevines superinfected by Grapevine fanleaf virus.  Virus Res.  2009;144;1-2  
•  Fuchs M, Meuret S, Stuhrmann NC, Schade G. [Dysphonia in children and adolescents]  HNO  2009;57;6  
•  Kullmann F, Hollerbach S, Dollinger MM, Harder J, Fuchs M, Messmann H, Trojan J, Gäbele E, Hinke A, Hollerbach C, Endlicher E. Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study.  Br. J. Cancer  2009;100;7  
•  Erhardt A, Deterding K, Benhamou Y, Reiser M, Forns X, Pol S, Calleja JL, Ross S, Spangenberg HC, Garcia-Samaniego J, Fuchs M, Enríquez J, Wiegand J, Stern J, Wu K, Kukolj G, Marquis M, Beaulieu P, Nehmiz G, Steffgen J. Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment.  Antivir. Ther. (Lond.)  2009;14;1  
•  Reddy DV, Sudarshana MR, Fuchs M, Rao NC, Thottappilly G. Genetically engineered virus-resistant plants in developing countries: current status and future prospects.  Adv. Virus Res.  2009;75  
•  Gottula J, Fuchs M. Toward a quarter century of pathogen-derived resistance and practical approaches to plant virus disease control.  Adv. Virus Res.  2009;75  

[ See timeline ] [ See all publications ]